氨己烯酸片(喜保宁)国内医院有吗

Are there any domestic hospitals? Vigabatrin tablets are currently not on the market in my country, so patients cannot purchase the drug in domestic pharmacies or hospital pharmacies.

Vigabatrin tablets (Vigabatrin) were approved by the US FDA as early as August 2009. They are suitable for monotherapy in children aged 1 month to 2 years old. Its potential benefits for infantile spasms outweigh the potential risk of vision loss, and it can be used as an auxiliary (additional) treatment (CPS) for adult patients with refractory complex partial epilepsy. On January 16, 2019, the FDA approved the launch of a generic version of Vigabatrin tablets.

The main component of vigabatrin tablets (vigabatrin) is vigabatrin (vigabatrin). Its mechanism of action is to irreversibly inhibit GABA aminotransferase (GABA-T) and increase the concentration of GABA in the brain to play its role. In the past two years, more and more children with TSC have effectively controlled epilepsy by using vigabatrin tablets (Vigabatrin). Western countries even use vigabatrin tablets (Vigabatrin) to prevent brain abnormalities in children with TSC who have not yet developed the disease. It can be seen that the effect is quite significant.

Vigabatrin tablets (Vigabatrin) need to be used under the guidance of a doctor with experience in treatment. The reaction after taking the medicine should be reported to the doctor in a timely manner. After patients took vigabatrin tablets (Vigabatrin), the incidence of visual field defects was very high (about one-third). This often occurs after several months to years of using vigabatrin. Visual field defects can be severe, which can have real consequences for the patient. Most patients with visual field loss have no obvious symptoms.

  Taking it for treatment may affect your ability to drive and use machinery. Generally, patients with uncontrolled epilepsy are not allowed to drive or operate potentially dangerous machinery. In view of reports of drowsiness during clinical use of vigabatrin, patients should be warned before initiating treatment with this drug.

Recommended related hot articles: /newsDetail/84567.html